Optimal Timing for Letrozole in Ovulation Induction
Start letrozole on cycle day 3 or day 5 of the menstrual cycle (or progesterone withdrawal bleeding), with day 5 initiation showing superior outcomes in recent evidence.
Recommended Starting Day
Day 5 initiation demonstrates better ovulation and conception rates compared to day 3 in women with PCOS. The most recent high-quality study found that starting letrozole on day 5 resulted in:
- Higher cumulative conception rates (75.9% vs 64.6%, rate ratio 1.174) 1
- Improved per-cycle ovulation rates (70.9% vs 60.6%) 1
- Greater endometrial thickness, which correlates with improved conception rates 1
- Shorter time-to-pregnancy among infertile women with PCOS 1
However, an earlier randomized trial found no significant differences between day 3 and day 5 initiation regarding ovulation rates (48.6% vs 32.4%) or pregnancy outcomes 2. Given the conflicting evidence, day 5 initiation appears preferable based on the most recent 2022 data showing measurable clinical advantages 1.
Guideline-Based Recommendations
Current clinical practice guidelines recommend letrozole as the primary method of pharmacological ovulation induction in women with PCOS, representing a shift from older recommendations that favored clomiphene citrate 3. This recommendation is supported by three major clinical practice guidelines 3.
Dosing Protocol
Standard dosing is 2.5 mg daily for 5 days, though recent evidence suggests alternative regimens may improve outcomes 4:
- Starting with 5 mg for 5 days or 2.5 mg for 10 days shows improved ovulation rates compared to the standard 2.5 mg for 5 days 4
- Extended 10-day courses achieve ovulation significantly sooner 4
- Cumulative ovulation rates exceed 84% across all regimens 4
Treatment Duration and Monitoring
- Continue the regimen for up to 3-6 ovulatory cycles 3, 1
- In non-responders, continue the same regimen from the previous cycle until pregnancy occurs 1
- Lifestyle modifications should be attempted for 3-6 months before pharmacological ovulation induction 3
Important Safety Considerations
Letrozole is contraindicated in pregnancy and can cause fetal harm, including spontaneous abortions and congenital birth defects 5. Critical safety measures include:
- Pregnancy testing is mandatory before starting treatment 5
- Effective contraception must be used during treatment and for at least 3 weeks after the last dose 5
- Women should not breastfeed while taking letrozole and for at least 3 weeks after the last dose 5
Recent meta-analyses provide some reassurance that letrozole does not increase congenital malformations compared to clomiphene citrate, natural conception, or gonadotropins, though the certainty of evidence remains very low 6.
Clinical Pitfalls to Avoid
- Do not use letrozole in obese women (BMI >35 kg/m²) according to some guidelines, which consider pharmacological ovulation induction contraindicated in this population 3
- Avoid combining letrozole with tamoxifen, as tamoxifen reduces letrozole plasma levels by 38% 5
- No dose adjustment is needed for renal impairment, but severe hepatic impairment (Child-Pugh C) results in two-fold increased exposure 5